Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Gel4Med Inc. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners. The prosecution involves 3 distinct art units, reflecting a diverse set of technical classifications for their pharmaceutical applications. This distribution across 3 art units suggests that the company's medical innovations are being evaluated by several different specialized divisions at the patent office.
REYNOLDS, FRED H is the busiest examiner, with 1 pending office action. Since there are 4 pending actions and 4 examiners, each examiner handles a single matter. The busiest examiner pending count of 1 confirms that the workload is not concentrated under one individual. For a practitioner, this requires a strategy that accounts for 4 different examiner styles and 3 different art unit environments.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (75%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
| KATAKAM, SUDHAKAR | 1 | 74.8% | +23.3% |
| BOWLES, DAVID PAUL | 1 | 69.6% | +28.1% |
| HELLMAN, KRISTINA M | 1 | 65.1% | +55.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682498 | FILMS FORMED FROM SELF-ASSEMBLING PEPTIDE HYDROGELS | REYNOLDS, FRED H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18040398 | TOPICAL AND PARENTERAL USE AND ADMINISTRATION OF SELF-ASSEMBLING AMPHIPHILIC PEPTIDE HYDROGELS | BOWLES, DAVID PAUL | 13d |
| 18682498 | FILMS FORMED FROM SELF-ASSEMBLING PEPTIDE HYDROGELS | REYNOLDS, FRED H | — |
| 18040380 | ANTIFUNGAL MATRIX FORMED FROM PEPTIDE HYDROGELS | KATAKAM, SUDHAKAR | — |
| 18040388 | ANTIMICROBIAL MATRIX FORMED FROM PEPTIDE HYDROGELS | HELLMAN, KRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1613 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682498 | FILMS FORMED FROM SELF-ASSEMBLING PEPTIDE HYDROGELS | REYNOLDS, FRED H | 1613 | §102§103§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18040380 | ANTIFUNGAL MATRIX FORMED FROM PEPTIDE HYDROGELS | KATAKAM, SUDHAKAR | 1658 | §103DP | Final Rejection | — | Pending | Feb 02, 2023 |
| 18040398 | TOPICAL AND PARENTERAL USE AND ADMINISTRATION OF SELF-ASSEMBLING AMPHIPHILIC PEPTIDE HYDROGELS | BOWLES, DAVID PAUL | 1654 | §102§103DP | Final Rejection | 13d | Pending | Feb 02, 2023 |
| 18040388 | ANTIMICROBIAL MATRIX FORMED FROM PEPTIDE HYDROGELS | HELLMAN, KRISTINA M | 1654 | §102§103§112DP | Non-Final OA | — | Pending | Feb 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGel4Med Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Fred H Reynolds has the most, with 1 of Gel4Med Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
